Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer

​Celcuity has reported topline outcomes from the PIK3CA mutant cohort of the Phase III VIKTORIA-1 clinical trial assessing gedatolisib combined with fulvestrant, with or without palbociclib, in patients with breast cancer.

The post Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

HeartBeam commences pilot study of new 12-lead ECG patch
Inhibrx announces positive interim results from HexAgon trial
Partner Therapeutics secures FDA approval for Bizengri
Latest foreign investment in UK highlights underserved potential of primary care technology
CoMira concludes lease agreement for plant in Sudair Industrial City, Saudi Arabia

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us